

Hepatic oxygen delivery-consumption relationship during anesthesia and hypoxemia in dogs

NOBUYUKI MATSUMOTO, YUTAKA MIZUMOTO, KÔICHIRO HORI, YASUO MURAKAMI, SINICHI NAKAMURA, HIROSHI NAGASAKA, and TAKAO HORI

Department of Anesthesiology, Saitama Medical School, 38 Morohongo, Moroyama, Iruma-gun, Saitama, 350-04 Japan

Key words: Hepatic oxygen delivery, Hepatic oxygen consumption, Anesthesia

The liver has been considered to be more resistant to hypoxemia than the brain, heart, or kidneys. This is chiefly because hepatic oxygen delivery (HDO_2) is more than adequate to meet hepatic oxygen consumption (HVO_2), approximately five times, at the steady state. Therefore, even though hypoxemia is induced, the liver can compensate for the decrease in HDO_2 by elevating the oxygen extraction ratio to the maximal level. HDO_2 , however, tends to be suppressed by inhalational anesthesia which usually decreases hepatic blood flow, and once hypoxemia develops due to decreased hepatic blood flow during inhalational anesthesia, the liver will not be able to compensate for the decrease in the HDO_2 . This can result in suppression of the HVO_2 to the critical point below which hepatic energy metabolism will be occasionally disturbed.

This study was designed to determine the critical HDO_2 level during halothane anesthesia compared with thiamylal anesthesia as a control. Another aim of this study was to measure oxygen metabolism in the liver during hypoxemia, since hepatic oxygen metabolism could be impaired by a decrease of HVO_2 below the critical HDO_2 .

Twenty-nine mongrel dogs were used in the study. Anesthesia was induced with ketamine 50 mg, i.m. and thiamylal 15 mg·kg⁻¹ i.v. Under controlled ventilation with pancuronium, maintaining $Paco_2$ at 30–40 mmHg, animals were anesthetized with N₂-O₂-1.5 MAC halothane or N₂-O₂-thiamylal 30 mg·kg⁻¹·h⁻¹ i.v. Following

laparotomy, the inspired oxygen concentration was gradually reduced from 21% to 15%, 12%, 10%, 8%, and 6%, which was achieved by mixing air and nitrogen, and maintained for 30 min at each fraction of inspired oxygen (F_{iO_2}) concentration during halothane or thiamylal anesthesia. At each period, hepatic arterial blood flow (HABF) and portal venous blood flow (PVBF) were assessed by electromagnetic flowmetry, and cardiac output was measured by the thermodilution technique. Blood gas tension was analyzed in arterial, portal venous, and hepatic venous blood obtained through the catheters placed in the each vessel. HDO_2 and HVO_2 were calculated by the following formulae [1].

$$HDO_2 = CaO_2 \times HABF + CpVO_2 \times PVBF$$

$$HVO_2 = (CaO_2 - ChVO_2) \times HABF + (CpVO_2 - ChVO_2) \times PVBF$$

In these formulae, CaO_2 , $CpVO_2$, and $ChVO_2$ represent the oxygen contents in the arterial, portal venous, and hepatic venous blood, respectively. The arterial ketone body ratio (AKBR, acetoacetate/ β -hydroxybutyrate) was measured at each F_{iO_2} as an indicator of hepatic energy charge [2].

Logarithmic correlation equations between HDO_2 and HVO_2 in the both anesthesia groups were calculated from HDO_2 and HVO_2 at each F_{iO_2} . Figure 1 depicts the correlation equation curves of the two anesthetic groups: $y = 1.01 + 1.23 \cdot \ln X$ ($r = 0.89$, $P < 0.01$) for the thiamylal group and $y = -0.76 + 1.76 \cdot \ln X$ ($r = 0.89$, $P < 0.01$) for the halothane group. The critical HDO_2 point, below which a small decrease in HDO_2 results in a larger drop in HVO_2 , corresponds with the shoulder of the linear regression curve. This critical HDO_2 on the halothane curve shifted down and to the right, approaching the point ($HDO_2 = 6.85 \text{ ml O}_2 \cdot \text{min}^{-1} \cdot 100 \text{ g}^{-1}$, $HVO_2 = 2.63 \text{ ml O}_2 \cdot \text{min}^{-1}$).

Address correspondence to: N. Matsumoto

Received for publication on August 29, 1994; accepted on December 16, 1994




Fig. 1. Hepatic oxygen delivery-consumption relationship curves of halothane (*dashed line*) and thiamylal (*solid line*) anesthesia. The halothane anesthesia curve shifts down and to the right with progression of hypoxemia. HDO₂, hepatic oxygen delivery; HVO₂, hepatic oxygen consumption

100 g⁻¹), whereas it was well maintained on the thiamylal curve at the point (4.88, 2.96). This critical HDO₂ appeared at an Fio₂ well below 0.1 on the thiamylal curve, but it appeared at an Fio₂ above 0.1 on the halothane curve.

In the present study, halothane anesthesia decreased both HDO₂ and HVO₂ more prominently than thiobarbiturate at equivalent Fio₂, and the regression curve of halothane was below that of thiamylal at all Fio₂. Moreover, the difference between the two curves was widened as hypoxemia progressed. Thiamylal maintained HVO₂ better against depression of HDO₂ by means of elevating the oxygen uptake ratio, unless HDO₂ shifted below the critical HDO₂ which was 4.88 ml O₂·min⁻¹·100 g⁻¹. On the other hand, halothane could not maintain HVO₂ at any HDO₂ below 6.85 ml O₂·min⁻¹·100 g⁻¹ which was the critical HDO₂ of

halothane. The present study also indicates that the minimum requirement of HVO₂ for the liver to survive would be between 2.6 and 3.0 ml O₂·min⁻¹·100 g⁻¹. The AKBR was more significantly suppressed in the halothane group than in the thiamylal group at all hypoxic Fio₂ levels, and particularly at Fio₂ = 0.08 the AKBR decreased to 0.3 in the halothane group whereas it was 0.6 in the thiamylal group. An AKBR below 0.4 for more than 48 h has been reported to be fatal in postoperative patients [2]. Nagano et al. [3] reported that halothane decreased hepatic oxygen demand but not always proportionally to the decrease in oxygen delivery. Also, some in vitro studies support our supposition that halothane decreases hepatic oxygen consumption, resulting in impairment of electron transport and mitochondrial energy production [4,5].

In conclusion, further decrease in HVO₂ with halothane anesthesia and a concomitant depletion of hepatic energy charge does not seem to provide any protection against hepatic oxygen deprivation but suggests that HVO₂ is reduced in cases of extremely poor HDO₂, and this decrease of HVO₂ can be life-threatening.

References

1. Hughes RL, Mathie RT, Campbell D, Fitch W (1979) Effect of hypercarbia on hepatic blood flow and oxygen consumption in the greyhound. *Br J Anaesth* 51:289-296
2. Ozawa K, Aoyama H, Yasuda K, Shimahara Y, Nakatani T, Tanaka J, Yamamoto M, Kamiyama Y, Tobe T (1983) Metabolic abnormalities associated with postoperative organ failure. A redox theory. *Arch Surg* 118:1245-1251
3. Nagano K, Gelman S, Parks DA, Bradley EL (1990) Hepatic oxygen supply-uptake relationship and metabolism during anesthesia in miniature pigs. *Anesthesiology* 72:902-910
4. Biebuyck JF, Lund P, Krebs HA (1972) The effects of halothane (2-bromo-2-chloro-1,1,1-trifluoroethane) on glycolysis and biosynthetic process of the isolated perfused rat liver. *Biochem J* 128:711-720
5. Miller RN, Hunter FE Jr (1970) The effect of halothane on electron transport, oxidative phosphorylation, and swelling in rat liver mitochondria. *Mol Pharmacol* 6:67-77